Compare Abeona Therapeutics Inc (ABEO) vs Applovin Corporation (APP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Applovin Corporation — how do they compare? Abeona Therapeutics Inc trades at $6.68 (market cap $373.32M), while Applovin Corporation trades at $516.61 (market cap $177.37B). The key difference: Applovin Corporation is far larger — about 475.1× Abeona Therapeutics Inc's market cap, and Abeona Therapeutics Inc is trading nearer its 52-week high, Applovin Corporation nearer its low. Which is the better fit depends on your goals.
| ABEO | APP | |
|---|---|---|
Market Cap | $373.32M | $177.37B |
Sector | Health | Technology |
52-Week High | $7.23 | $733.60 |
52-Week Low | $4.17 | $335.10 |
Enterprise Value | $228.22M | $178.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
AppLovin (APP) trades at $543.79, up 3.17% with strong technical momentum and bullish analyst sentiment. The stock demonstrates exceptional profitability with 64.29% net income margins and consistent earnings beats. Recent Q1 2026 results showed $3.56 EPS beating expectations, while technical indicators signal bullish momentum with key resistance at $554. The company's AI-powered advertising platform drives robust revenue growth, with 2026 revenue projected at $6.2 billion.
AppLovin presents compelling growth potential with 88% analyst buy ratings and $644.09 consensus price target, offering 18% upside. However, premium valuations (P/E 47.29, P/S 30.03) and competitive pressures in mobile advertising represent key risks. The upcoming Q2 2026 earnings on August 5th will be crucial for validating the AI growth narrative and sustaining current momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Applovin Corporation
AppLovin provides a software platform for mobile app developers to market, monetize, and analyze their apps. Its AI-powered tools help developers grow their business by connecting them with global advertising networks.
Read more on APP →
